Hormone`s role in development and energy regulation (Review Article)

Yıl 2022, Cilt: 3 Sayı: 3, 1 - 9, 24.08.2022

Ishtar Imad Suhail Bayati

https://doi.org/10.55549/zbs.1166103

Öz

Asprosin, in addition to performing a glucogenic function, is a centrally acting orexigenic hormone that represents a potential therapeutic target for the treatment of obesity and diabetes. Perturbations in the action of T3 and T4 affect normal metabolic pathways. The sensitivity of lipid biomarkers such as LDL-C, HDL-C, TC, TG, Apo-A, and Apo-B after rehabilitation of the thyroid profile to achieve a euthyroid state was determined.

Anahtar Kelimeler

Asprosin, T3, T4, HDL-C, TC, Apo-A, Apo-B, Adropin, preptin

Kaynakça

• Mogulkoc, Rasim & Dasdelen, Dervis & Baltaci, Saltuk & Baltaci, Abdulkerim Kasim & Sivrikaya, Abdullah. (2020). The effect of thyroid dysfunction and treatment on drop-in, asprosin, and preptin levels in rats. Hormone Molecular Biology and Clinical Investigation. -1. 10.1515/hmbci-2020-0058.
• Naiemian, S., Naeemipour, M., Zarei, M. et al. (2020). Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr 12, 65https://doi.org/10.1186/s13098-020-00564-w.
• Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, Saha PK, Lee ME, Phillips KJ, Jain M, Jia P, Zhao Z, Farias M, Wu Q, Milewicz DM, Sutton VR, Moore DD, Butte NF, Krashes MJ, Xu Y, Chopra AR. (2017 ).
• Asprosin is a centrally acting orexigenic hormone. Nat Med. Dec;23(12):1444-1453. doi: 10.1038/nm.4432. Epub 2017 Nov 6. PMID: 29106398; PMCID: PMC5720914.
• Naiemian, Shakiba and Naeemipour, Mohsen, el al . (2020). The serum concentration of asprosin in new-onset type 2 diabetes. Diabetology & Metabolic Syndrome. 65: 12: 1. Asprosin, a newly identified adipokine, is pathologically increased in individuals with insulin resistance. However, the available evidence on the association of asprosin and type 2 diabetes mellitus (T2DM) status is still scarce. Therefore, this study aimed to determine the relationship between serum concentrations of asprosin and T2DM status.1758-5996.https://doi.org/10.1186/s13098-020-00564-w.bvgbbfB.
• K. Ugur, F. Erman, S. Turkoglu, Y. Aydin, A. Aksoy, A. Lale, Z.K. Karagöz, İ. Ugur, R.F. Akkoc, M. Yalniz. (2022). Asprosin, visfatin, and subfatin as new biomarkers of obesity and metabolic syndrome. Eur Rev Med Pharmacol Science. Vol. 26 - N. 6. 2124-2133.DOI: 10.26355/eurrev_202203_28360.
• Al-Daghri, Nasser M., Reem M.I. Alokeel, Abir Alamro. (2022). Serum asprosin levels are associated with obesity and insulin resistance in Arab adults. Journal of King Saud University – Science. Volume 34, Issue 1.
• Atici E, Menevse E, Baltaci AK, Mogulkoc R. (2018 ). Both experimental hypothyroidism and hyperthyroidism increase cardiac irisin levels in rats. Bratislavske Lekarske Listy.119(1):32-35. DOI: 10.4149/bll_2018_007. PMID: 29405728.
• Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. (2016). Asprosin, is a fasting-induced glucogenic protein hormone. Cell. 165:566–79. doi: 10.1016/j.cell.2016.02.063.
• Lee T, Yun S, Jeong JH, Jung TW. (2019). Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol. 486:96–104. doi: 10.1016/j.mce.2019.03.001.
• Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. (2017). Asprosin is a centrally acting orexigenic hormone. Nat Med. 23:1444–53. doi: 10.1038/nm.4432.
• Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, et al. (2019). Asprosin attenuates the insulin signaling pathway through PKCdelta-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 234:20888–99. doi: 10.1002/jcp.28694.
• Amer Diabet A. (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care. 37:S81–90. doi: 10.2337/dc14-S081.
• Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. (2018) Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Med Inflam. 2018:9471583. doi: 10.1155/2018/9471583.
• Zhang X, Jiang H, Ma X, Wu H. (2019). Increased serum level and impaired response to glucose fluctuation of asprosin are associated with type 2 diabetes mellitus. J Diabetes Investig. doi: 10.1111/jdi.13148.
• Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. (2018). Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Med Inflam. 2018:7375294. doi: 10.1155/2018/7375294.
• Groener JB, Valkanou A, Kender Z, Pfeiffenberger J, Kihm L, Fleming T, et al. (2019). Asprosin response in hypoglycemia is not related to hypoglycemia unawareness but rather to insulin resistance in type 1 diabetes. PLoS ONE. 14:e0222771. doi: 10.1371/journal.pone.0222771.
• Baykus Y, Yavuzkir S, Ustebay S, Ugur K, Deniz R, Aydin S. (2019). Asprosin in the umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation, and macrosomic fetus. Peptides. 120:170132. doi: 10.1016/j.peptides.2019.170132.
• Ko JR, Seo DY, Kim TN, Park SH, Kwak HB, Ko KS, et al. (2019). Aerobic exercise training decreases hepatic asprosin in diabetic rats. J Clin Med. 8:666. doi: 10.3390/jcm8050666.
• Titchenell PM, Lazar MA, Birnbaum MJ. (2017). Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol Metab. 28:497–505. doi: 10.1016/j.tem.2017.03.003.
• Unger RH. (2003). Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab. 14:398–403. doi: 10.1016/j.tem.2003.09.008.
• Wang CY, Lin TA, Liu KH, Liao CH, Liu YY, Wu VC, et al. (2019). Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obesity. 43:1019–25. doi: 10.1038/s41366-018-0248-1.
• Wang M, Yin C, Wang L, Liu Y, Li H, Li M, et al. (2019). Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity. Ann Nutr Metab. 75:205–12. doi: 10.1159/000503808.
• Ugur K, Aydin S. (2019). Saliva and blood asprosin hormone concentrations are associated with obesity. Int J Endocrinol. 2019:2521096. doi: 10.1155/2019/2521096.
• Ma H, Zhang G, Mou C, Fu X, Chen Y. (2018). Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate-induced obese mice. Front Pharmacol. 9:156. doi: 10.3389/fphar.2018.00156.
• Long W, Xie X, Du C, Zhao Y, Zhang C, Zhan D, et al. (2019). Decreased circulating levels of asprosin in obese children. Horm Res Paediatr. 91:271–7. doi: 10.1159/000500523.